This study will be the first trial to evaluate the safety and efficacy of dapagliflozin
treatment in preventing readmissions/ER visits/urgent clinic visits, and death in patients
with and without T2D after admission for heart failure. Treatment with SGLT2-i has been shown
to reduce both heart failure hospitalizations and mortality in patients with established
heart disease. However, the time of initiation of SGLT2-i therapy has not been evaluated in
patients with HF. In addition, the impact of treatment on HF symptoms quality of life,
resource utilization, and cost-effectiveness of dapagliflozin versus placebo will be
evaluated. The results of this study have great potential to impact and facilitate care and
to change current clinical guidelines in the management of patients with heart failure.